All In Biotech

Investigational drug · Phase 2

Alisertib

Also called: PB-8237, MLN8237

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

65

Any phase or sponsor naming "Alisertib"

First trial start

2024

Feb 8, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Alisertib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Metastatic Breast Cancer
  • Recurrent Breast Cancer
  • Small Cell Lung Cancer
  • Small Cell Lung Cancer ( SCLC )

Approved drugs for the same conditions: Breast cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Alisertib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 449 on PubMed

Also in development for Hormone Receptor Positive HER-2 Negative Breast Cancer

  • SerplulimabHLX10, HLX43Phase 325 trials

    Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage

  • EP0062Phase 21 trial

    Ellipses Pharma · Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.